204 related articles for article (PubMed ID: 31131695)
21. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
[TBL] [Abstract][Full Text] [Related]
23. Correlation between telomerase reverse transcriptase messenger RNA expression and survival of patients with papillary thyroid carcinoma.
Kwon JH; Yi JW
Surgery; 2021 Jan; 169(1):43-49. PubMed ID: 32641280
[TBL] [Abstract][Full Text] [Related]
24. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
25. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
26. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors.
Umbricht CB; Conrad GT; Clark DP; Westra WH; Smith DC; Zahurak M; Saji M; Smallridge RC; Goodman S; Zeiger MA
Clin Cancer Res; 2004 Sep; 10(17):5762-8. PubMed ID: 15355904
[TBL] [Abstract][Full Text] [Related]
27. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.
Umbricht CB; Saji M; Westra WH; Udelsman R; Zeiger MA; Sukumar S
Cancer Res; 1997 Jun; 57(11):2144-7. PubMed ID: 9187112
[TBL] [Abstract][Full Text] [Related]
28. TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma.
Paulsson JO; Olander A; Haglund F; Zedenius J; Juhlin CC
Endocr Pathol; 2018 Dec; 29(4):380-383. PubMed ID: 30306386
[No Abstract] [Full Text] [Related]
29. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
30.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
31. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas.
Dettmer M; Vogetseder A; Durso MB; Moch H; Komminoth P; Perren A; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2013 Jan; 98(1):E1-7. PubMed ID: 23150679
[TBL] [Abstract][Full Text] [Related]
32. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.
Zeiger MA; Smallridge RC; Clark DP; Liang CK; Carty SE; Watson CG; Udelsman R; Saji M
Surgery; 1999 Dec; 126(6):1195-8; discussion 1198-9. PubMed ID: 10598207
[TBL] [Abstract][Full Text] [Related]
33. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
34. TERT Promoter Mutations in Thyroid Cancer.
Alzahrani AS; Alsaadi R; Murugan AK; Sadiq BB
Horm Cancer; 2016 Jun; 7(3):165-77. PubMed ID: 26902827
[TBL] [Abstract][Full Text] [Related]
35. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
37. [Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value].
Selivanova LS; Volganova KS; Abrosimov AY
Arkh Patol; 2016; 78(1):62-69. PubMed ID: 27077147
[TBL] [Abstract][Full Text] [Related]
38. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
40. Human telomerase reverse transcriptase expression in Diff-Quik-stained FNA samples from thyroid nodules.
Siddiqui MT; Greene KL; Clark DP; Xydas S; Udelsman R; Smallridge RC; Zeiger MA; Saji M
Diagn Mol Pathol; 2001 Jun; 10(2):123-9. PubMed ID: 11385322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
